NASDAQ:IRD Opus Genetics Q3 2026 Earnings Results & Report $4.18 -0.02 (-0.36%) As of 02:16 PM Eastern This is a fair market value price provided by Massive. Learn more. Opus Genetics missed analyst expectations on both earnings and revenue in its Q3 2026 results, released November 10, 2026. The company reported EPS of -$0.46 versus the -$0.14 consensus estimate, while revenue of $1.14 million fell short of the $1.55 million estimate by $410.00 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 10, 2026TimeBefore Market OpensConference Call7:00 AM ET Opus Genetics EPS ResultsActual EPS-$0.46Consensus EPS -$0.14Beat/MissMissed by -$0.32One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersOpus Genetics Revenue ResultsActual Revenue$1.14 millionExpected Revenue$1.55 millionBeat/MissMissed by -$410.00 thousandYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) Opus Genetics Q3 2026 Earnings FAQ Did Opus Genetics beat earnings estimates for Q3 2026? Opus Genetics (NASDAQ:IRD) reported earnings of -$0.46 per share for Q3 2026, missing the consensus estimate of -$0.14. The report was announced on Tuesday, November 10, 2026. What was Opus Genetics' revenue for Q3 2026? Opus Genetics reported revenue of $1.14 million for Q3 2026, against a consensus estimate of $1.55 million. Opus Genetics Earnings HeadlinesOpus Genetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 20264 hours ago | marketscreener.comMOpus Genetics Announces Financial Results for Third Quarter 2026 and Provides Corporate UpdateNovember 10 at 7:00 AM | globenewswire.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.November 10 at 1:00 AM | Weiss Ratings (Ad)Opus Genetics (IRD) Set to Release Earnings on WednesdayNovember 10 at 2:43 AM | americanbankingnews.comOpus Genetics (NASDAQ:IRD) Rating Lowered to Sell at Wall Street ZenNovember 7 at 1:30 AM | americanbankingnews.comOpus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Inherited Retinal DiseasesNovember 5, 2026 | globenewswire.comSee More Opus Genetics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Opus Genetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Opus Genetics and other key companies, straight to your email. Email Address About Opus GeneticsOpus Genetics (NASDAQ:IRD) is a clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases (IRDs), a group of rare genetic disorders that can cause progressive vision loss and blindness. The company’s research is aimed at addressing the underlying genetic causes of these conditions rather than treating only their symptoms. Its pipeline includes investigational ophthalmic gene therapies designed for specific IRD-causing mutations, including programs targeting conditions associated with the NR2E3 and BEST1 genes. Opus Genetics is advancing these candidates through preclinical and clinical development and has used gene therapy technologies, including assets obtained through collaborations and licensing arrangements, to expand its development portfolio. Opus Genetics was established in 2017 and is based in Durham, North Carolina. The company’s programs are primarily directed toward patients with rare retinal diseases in the United States and other markets where clinical development and regulatory approvals may support future commercialization. Ben Yerxa serves as chief executive officer.View Opus Genetics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
